Heparin Anticoagulated Articles & Analysis
2 news found
(CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (“PLA”) with Quebec Minister of Health, for the listing and public reimbursement of Redesca and Redesca HP, its low molecular weight heparin (“LMWH”) ...
The company was granted a US patent “Platelet Analysis System” (US10, 012,658 B2), and the PCT of the patent “Heparin-induced thrombocytopenia test” (PCT/IB2018/052179) was recently published. Heparin-induced thrombocytopenia (HIT) is a potentially lethal disorder caused by heparin, the most prescribed injectable ...